Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma

Journal of Translational Medicine

Volumn 4, Issue , 2006, Pages

  Markovic, Svetomir N ^a   Dietz, Allan B ^a,b   Greiner, Carl W ^a   Maas, Mary L ^a   Butler, Greg W ^a   Padley, Douglas J ^a   Bulur, Peggy A ^b   Allred, Jacob B ^b   Creagan, Edward T ^a   Ingle, James N ^a   Gastineau, Dennis A ^a   Vuk Pavlovic, Stanimir ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD14 ANTIGEN; COMPLEMENTARY DNA; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOPROTEIN GP 100; MELAN A; MESSENGER RNA; MONOPHENOL MONOOXYGENASE;

ABDOMINAL PAIN; ADVANCED CANCER; ANOREXIA; ARTHRALGIA; ARTICLE; BLEEDING; BONE MARROW CELL; BONE PAIN; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL ISOLATION; CELL MATURATION; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLOSTOMY; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DIARRHEA; DRUG SAFETY; DRUG SYNTHESIS; ELECTROPORATION; FATIGUE; FEASIBILITY STUDY; GENE AMPLIFICATION; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; INJECTION SITE REACTION; LEUKAPHERESIS; MELANOMA; MYALGIA; NAUSEA; PHENOTYPE; POLYMERASE CHAIN REACTION; PROMOTER REGION; RNA EXTRACTION; RNA ISOLATION; RNA TRANSCRIPTION; SPEECH DISORDER; STANDARDIZATION; VOMITING; WOUND INFECTION;

EID: 33749168691     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-4-35     Document Type: Article

References (30)

1. Banchereau J, Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nature Rev Immunol 2005, 5:296-306.
2. Figdor CG, de Vries IJM, Lesterhuis WJ, Melief CJM: Dendritic cell immunotherapy: mapping the way. Nature Med 2004, 10:475-480.
3. Fecci PE, Mitchell DA, Archer GE, Morse MA, Lyerly HK, Bigner DD, Sampson JH: The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neuro-Oncol 2003, 64:161-176.
4. Gilboa E, Vieweg J: Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004, 199:251-263.
5. Liao X, Li Y, Bonini C, Nair S, Gilboa E, Greenberg PD, Yee C: Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther 2004, 9:757-764.
6. Schaft N, Dorrie J, Thumann P, Beck VE, Muller I, Schultz ES, Kampge E, Dieckmann D, Schuler G: Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol 2005, 174:3087-3097.
7. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton AJ, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19:3635-3648.
8. National Cancer Institute: Surveillance, epidemiology and end results database. [http://www.seer.cancer.gov/statfacts/html/melan/ html?statfacts_page=melan.hjtml&x-8&y=12].
9. Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature 2001, 411:380-384.
10. Rosenberg S: Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst 1985, 75(4):595-603.
11. Wolchok JD, Livingston PO: Vaccines for melanoma: translating basic immunology into new therapies. Lancet Oncol 2001, 2:205-211.
12. High WA, Stewart D, Wilbers CRH, Cockerell CJ, Hoang MP, Fitzpatrick JE: Completely regressed primary cutaneous malignant melanoma with nodal and/ or visceral metastases: A report of 5 cases and assessment of the literature and diagnostic criteria. J Am Acad Derm 2005, 53:89-100.
13. Lotze MT, Shurin M, Davis I, Amoscato A, Storkus WJ: Dendritic cell based immunotherapy of cancer. Adv Exp Med Biol 1997, 417:551-569.
14. Ingram SB, O'Rourke MG: DC therapy for metastatic melanoma. Cytotherapy 2004, 6:148-153.
15. Nestle FO, Banchereau J. Hart D: Dendritic cells: On the move from bench to the bedside. Nature Med 2001, 7:761-765.
16. Boczkowski D, Nair S, Snyder D, Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996, 184:465-472.
17. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997, 186:1177-1182.
18. Saeboe-Larssen S, Fossberg E, Gaudernack G: mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Meth 2002, 259:191-203.
19. van Tendeloo VFI, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, Van Bockstaele DR, Berneman ZN: Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001, 98:49-56.
20. Lohmann S, Galle K, Knop, J, Enk AH: CD83+ human dendritic cells transfected with tumor peptide cDNA by electroporation induce specific T-cell responses: A potential tool for gene immunotherapy. Cancer Gene Ther 2000, 7:605-614.
21. Kyte JA, Kvalheim G, Aamdal S, Saeboe-Larssen S, Gaudernack G: Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. Cancer Gene Ther 2005, 12:579-591.
22. Padley DJ, Dietz AB, Gastineau DA, Vuk-Pavlovic S: Mature myeloid dendritic cells for clinical use prepared from CD14-positive cells isolated by immunomagnetic adsorption. J Hematother Stem Cell Res 2001, 10:427-429.
23. Dietz AB, Padley DJ, Butler GW, Maas ML, Greiner CW, Gastineau DA, Vuk-Pavlovic S: Clinical-grade manufacturing of dendritic cells from CD14+ precursors: Experience from phase 1 clinical trial in chronic myelogenous leukemia and malignant melanoma. Cytotherapy 2004, 6:563-570.
24. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E: Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000, 60:1028-1034.
25. Therasse P, Arbuck S, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
26. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Sem Rad Oncol 2003, 13:176-181.
27. March JC, Rao G, Bentley WE: Biotechnological applications of green fluorescent protein. Appl Microbiol Biotechnol 2003, 62:303-315.
28. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
29. Feroze-Merzoug F, Berquin IM, Dey J, Chen YQ: Peptidylprolyl isomerase A (PPIA) as a preferred internal control over GAPDH and beta-actin in quantitative RNA analyses. Biotechniques 2002, 32:776-782.
30. Bernsen MR, Dijkman HBPM, de Vries E, Figdor CG, Ruiter DJ, Adema GJ, van Muijen GN: Identification of multiple mRNA and DNA sequences from small tissue samples isolated by laser-assisted microdissection. Lab Investig 1998, 78:1267-1273.